| Hazard Information | Back Directory | [Uses]
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
[1][2][3]. | [in vivo]
Conatumumab (0-100 μg, i.p., twice weekly) inhibits tumor growth in mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors[2].
Conatumumab (2.5 μg, i.p., three times per week) enhances the antitumor activity of chemotherapeutics (CPT11, HY-16562) (80 mg/kg) in Colo 205 xenograft[2].
| Animal Model: | Mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors[2] | | Dosage: | 0, 0.1, 0.3, 1, 3, 10, 30, 100 μg | | Administration: | Intraperitoneal injection (i.p.), twice weekly. | | Result: | Dose-dependently inhibited tumor growth.
Induced caspase-3 activation in tumors (determined by IHC).
|
| [References]
[1] Herbst RS, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 1;16(23):5883-91. DOI:10.1158/1078-0432.CCR-10-0631
[2] Kaplan-Lefko PJ, et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther. 2010 Apr 15;9(8):618-31. DOI:10.4161/cbt.9.8.11264 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|